Ascentage Pharma Group International (AAPG) Invested Capital: 2022-2024

  • Ascentage Pharma Group International's Invested Capital rose 2.33% to $262.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $262.0 million, marking a year-over-year increase of 2.33%. This contributed to the annual value of $262.0 million for FY2024, which is 0.44% up from last year.
  • Per Ascentage Pharma Group International's latest filing, its Invested Capital stood at $262.0 million for Q4 2024, which was up 2.33% from $256.0 million recorded in Q4 2023.
  • Ascentage Pharma Group International's 5-year Invested Capital high stood at $307.1 million for Q4 2022, and its period low was $256.0 million during Q4 2023.
  • Over the past 3 years, Ascentage Pharma Group International's median Invested Capital value was $262.0 million (recorded in 2024), while the average stood at $275.0 million.
  • Its Invested Capital has fluctuated over the past 5 years, first fell by 16.63% in 2023, then rose by 2.33% in 2024.
  • Over the past 3 years, Ascentage Pharma Group International's Invested Capital (Quarterly) stood at $307.1 million in 2022, then fell by 16.63% to $256.0 million in 2023, then rose by 2.33% to $262.0 million in 2024.
  • Its last three reported values are $262.0 million in Q4 2024, $256.0 million for Q4 2023, and $307.1 million during Q4 2022.